Neoadjuvant-Intent Immunotherapy in Advanced, Resectable Cutaneous Squamous Cell Carcinoma

2024

CSCC

In this article, we present a cohort study of patients treated with neoadjuvant cemiplimab or pembrolizumab for advanced cSCC

Author

Kim EY, Ruiz ES, DeSimone MS, Shalhout SZ, Hanna GJ, Miller DM, Schmults C, Rettig EM, Foreman RK, Sethi R, Thakuria M, Silk Ann W

Published

March 28, 2024

Doi

10.1001/jamaoto.2024.0259

Citation

BibTeX citation:

@article{2024,
  author = {},
  publisher = {JAMA},
  title = {Neoadjuvant-Intent {Immunotherapy} in {Advanced,}
    {Resectable} {Cutaneous} {Squamous} {Cell} {Carcinoma}},
  journal = {JAMA Otolaryngology-Head \& Neck Surgery},
  date = {2024-03-28},
  url = {https://themillerlab.io/publications/Neoadjuvant-Intent_ Immunotherapy_in_Advanced_Resectable_CSCC},
  doi = {10.1001/jamaoto.2024.0259},
  langid = {en}
}

For attribution, please cite this work as:

“Neoadjuvant-Intent Immunotherapy in Advanced, Resectable Cutaneous Squamous Cell Carcinoma.” 2024. JAMA Otolaryngology-Head & Neck Surgery, March. https://doi.org/10.1001/jamaoto.2024.0259.